Curdlan sulphate in human severe/cerebral Plasmodium falciparum malaria

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 99, Issue 5, 2005, Pages 333-340

  Havlik, I ^a   Looareesuwan, S ^b   Vannaphan, S ^b   Wilairatana, P ^b   Krudsood, S ^b   Thuma, P E ^c   Kozbor, D ^d   Watanabe, N ^e   Kaneko, Y ^f,g  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Macha Malaria Research Institute   (Zambia)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f AJINOMOTO CO INC   (Japan)

^g KINKI UNIVERSITY   (Japan)

Author keywords

Cerebral malaria; Curdlan sulphate; Plasmodium falciparum; Severe malaria; Thailand

Indexed keywords

ARTESUNATE; CURDLAN; HEPARIN; PLACEBO; POLYSACCHARIDE SULFATE;

ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ANTIMALARIAL ACTIVITY; ARTICLE; BLOOD CLOTTING DISORDER; BRAIN MALARIA; CELL ADHESION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; MALE; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PLASMODIUM FALCIPARUM; PREDICTION; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; BETA-GLUCANS; CHILD; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HUMANS; MALARIA, CEREBRAL; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITEMIA; SESQUITERPENES; TREATMENT OUTCOME;

ARTESUNATE; PLASMODIUM FALCIPARUM;

EID: 14944369440     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2004.05.005     Document Type: Article

References (20)

1. G.A. Butcher C.R. Parish W.B. Cowden Inhibition of growth in vitro of Plasmodium falciparum by complex polysaccharides Trans. R. Soc. Trop. Med. Hyg. 82 1988 558-559
2. J. Carlson H. Erke H. Helmby J. Gysin B.M. Greenwood M. Wahlgren Disruption of Plasmodium falciparum erythrocyte rosettes by standard heparin and heparin devoid of anticoagulant activity Am. J. Trop. Med. Hyg. 46 1992 595-602
3. S.G. Evans D. Morrison Y. Kaneko I. Havlik The effect of curdlan sulphate on development in vitro of Plasmodium falciparum Trans. R. Soc. Trop. Med. Hyg. 92 1998 87-89
4. M. Gordon M. Guralnik Y. Kaneko T. Mimura M. Baker W. Lang Phase I study of curdlan sulfate - an HIV inhibitor. Tolerance, pharmacokinetics and effects on coagulation and on CD4 lymphocytes J. Med. 25 1994 163-180
5. M. Gordon S. Deeks C. De Marzo J. Goodgame M. Guralnik W. Lang T. Mimura D. Pearce Y. Kaneko Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: Indication of anti-CMV activity with low toxicity J. Med. 28 1997 108-128
6. I. Havlik S. Rovelli Y. Kaneko The effect of curdlan sulphate on in vitro growth of Plasmodium falciparum Trans. R. Soc. Trop. Med. Hyg. 88 1994 686-687
7. I. Havlik G. Mabeza D. Richardt P. Thuma P. Mabeza G. Biemba C. Rosmarin D. Alexander R. van Zyl P. Mbachundu G. Simwanzi H. Mbewe N. Arangies R. Schall D. Kozbor V. Gordeuk Y. Kaneko Curdlan sulfate in human asymptomatic malaria Naunyn-Schmiedeberg's Archives of Pharmacology 358 Suppl. 2 1998 R526
8. I. Igarashi F.K. Njonge Y. Kaneko Y. Nakamura Babesia bigemina: In vitro and in vivo effects of curdlan sulfate on growth of parasites Exp. Parasitol. 90 1998 290-293
9. P.P. Jagodzinski R. Wiaderkiewicz G. Kurzawski M. Kloczewiak H. Nakashima E.E. Hyjek N. Yamamoto T. Uryu Y. Kaneko M.R. Posner D. Kozbor Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection in vitro Virology 202 1994 735-745
10. Y. Kaneko O. Yoshida R. Nakakawa T. Yoshida M. Ate S. Oghihara S. Shioya Y. Matsuzawa N. Nagashima Y. Irie T. Mimura H. Shinkai N. Yasuda K. Matsuzaki T. Uryu N. Yamamoto Inhibition of HIV-1 infectivity with curdlan sulfate in vitro Biochem. Pharmacol. 39 1990 793-797
11. K.N. Masihi K. Madaj H. Hintelmann G. Gast Y. Kaneko Down-regulation of tumor necrosis factor-alpha, moderate reduction of interleukin-1 beta, but not interleukin-6 or interlekin-10, by glucan immunomodulators curdlan sulfate and lentinan Int. J. Immunopharmacol. 19 1997 463-468
12. M. Munir H. Tjandra T.H. Rampengan I. Mustadjab F.H. Wulur Heparin in treatment of cerebral malaria Paediatr. Indones. 20 1980 47-50
13. T. Naito M. Okada H. Ogasawara H. Kaneko T. Hishikawa T. Matsumoto I. Sekigawa H. Hashimoto Y. Kaneko Curdlan sulfate induces the downmodulation of chemokine receptors leading to suppression of HIV infection J. Acquir. Immune Defic. Syndr. 26 2001 512-513
14. T.H. Rampengan Cerebral malaria in children. Comparative study between heparin, dexamethasone and placebo Paediatr. Indones. 31 1991 59-66
15. A. Rowe R. Berendt K. Marsh C.I. Newbold Plasmodium falciparum: A family of sulphated glycoconjugates disrupts erythrocyte rosettes Exp. Parasitol. 79 1994 506-516
16. N.J. White Delaying anti-malarial drug resistance with combination chemotherapy Parassitologia. 41 1999 301-308
17. P. Wilairatana S. Looareesuwan APACHE II scoring for predicting outcome in cerebral malaria J. Trop. Med. Hyg. 98 1995 256-260
18. WHO Severe and complicated malaria Trans. R. Soc. Trop. Med. Hyg. 80 Suppl. 1986
19. WHO Severe falciparum malaria Trans. R. Soc. Trop. Med. Hyg. 94 Suppl. 1 2000
20. L. Xiao C. Yang P.S. Patterson V. Udhayakumar A.A. Lal Sulfated polyanions inhibit invasion of erythrocytes by plasmodial merozoites and cytoadherence of endothelial cells to parasitized erythrocytes Infect. Immun. 64 1996 1373-1378